Carcinosarcoma clinical trials at UCSF
1 research study open to eligible people
Carcinosarcoma is a rare cancer that contains both carcinoma and sarcoma cells. UCSF is conducting a trial to evaluate the safety and effects of a new drug called BLU-222 in advanced solid tumors. The study also examines how the drug is absorbed and processed in the body.
Showing trials for
(VELA) Study of BLU-222 in Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
San Francisco, California and other locations
Last updated: